<DOC>
	<DOC>NCT01074255</DOC>
	<brief_summary>This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation. Its aim is to reconfirm the clinical usefulness of EMEMD (aprepitant) through collecting the safety information according to the Re-examination Regulation for New Drugs.</brief_summary>
	<brief_title>Re-examination Study of EMEND (Aprepitant) (MK-0869-184)</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Participants who are treated with EMEND for the first time as per the EMEND label Contraindication to EMEND</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Post-chemotherapy</keyword>
</DOC>